Company profile: Gabather
1.1 - Company Overview
Company description
- Provider of research and development of innovative therapeutics for neuropsychiatric disorders, focusing on pro-cognitive drug candidates targeting GABAA receptor systems for central nervous system disorders, including GT-002, a small-molecule GABAA receptor PAM in clinical development to improve learning and memory, reduce anxiety, and promote social interaction.
Products and services
- GABAA Receptor-Targeted Drug Discovery: Mechanism-specific program developing novel pro-cognitive drug candidates targeting GABAA receptor systems for the treatment of central nervous system disorders
- GT-002: Clinical-stage small molecule GABAA receptor Positive Allosteric Modulator (PAM) that improves learning and memory, reduces anxiety, and promotes social interaction, currently in clinical development for neuropsychiatric disorders
- Neuropsychiatric Therapeutics R&D: CNS-focused research and development creating innovative and effective therapeutics for neuropsychiatric disorders for the treatment of central nervous system disorders
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Gabather
Mitokinin
HQ: United States
Website
- Description: Provider of biotechnology R&D focused on medicinal chemistry to generate kinetin analogs optimized for activating PINK1, with plans to develop these analogs or optimized variants to treat Parkinson's disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mitokinin company profile →
IntraBio
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and candidates, including IB1001 (orally administered N-Acetyl-Leucine) for rare neurological disorders such as NPC, GM1/GM2 gangliosidosis and inherited cerebellar ataxias; IB2000 and IB5000 for Ménière’s disease with clinical efficacy and safety in observational studies; IB3000 (NAADP analogues/agonists) with pre-clinical potential for Type 2 Diabetes, autism and neurodegenerative disorders; IB4000 (UDCA) for NPC liver dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IntraBio company profile →
Uman Diagnostics
HQ: Sweden
Website
- Description: Provider of neurofilament light (Nf-L) antibodies and ELISA kits to advance the development of therapeutics and diagnostics for neurodegenerative conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Uman Diagnostics company profile →
Ionix Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of discovery and development of new analgesic medicines for the treatment of acute and chronic pain. Based in Cambridge, UK, Ionix Pharmaceuticals leverages proprietary drug targets and state-of-the-art chemistry to alleviate pain associated with trauma and operative procedures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ionix Pharmaceuticals company profile →
BioQ Pharma
HQ: United States
Website
- Description: Provider of pre-filled, ready-to-use infusion delivery systems and medicines. Offerings include invenious, a platform for infusible medicines to simplify infusion and enhance safety and sterility; Ropivacaine Readyfusor, a pre-filled infusion for surgical procedures as a safer, more efficient alternative to fillable pain pumps; and invenious/propofol, a ready-to-use infusion with programmable flow and bolus for procedural anesthesia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioQ Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Gabather
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Gabather
2.2 - Growth funds investing in similar companies to Gabather
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Gabather
4.2 - Public trading comparable groups for Gabather
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →